These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30883325)

  • 21. Cost-Sharing Rates Increase During Deep Recession: Preliminary Data From Greece.
    Gouvalas A; Igoumenidis M; Theodorou M; Athanasakis K
    Int J Health Policy Manag; 2016 May; 5(12):687-692. PubMed ID: 28005548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effects of Cost Sharing on Adherence to Medications Prescribed for Concurrent Use: Do Definitions Matter?
    Sacks NC; Burgess JF; Cabral HJ; McDonnell ME; Pizer SD
    J Manag Care Spec Pharm; 2015 Aug; 21(8):678-87. PubMed ID: 26233540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Backlash Against Copay Accumulators.
    Silverman E
    Manag Care; 2018 Sep; 27(9):15. PubMed ID: 30216152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Medicare prescription drug benefit: how will the game be played?
    Huskamp HA; Rosenthal MB; Frank RG; Newhouse JP
    Health Aff (Millwood); 2000; 19(2):8-23. PubMed ID: 10718018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do interventions that address patient cost-sharing improve adherence to prescription drugs? A systematic review of recently published studies.
    Sensharma A; Yabroff KR
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):263-277. PubMed ID: 30628493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Scaling cost-sharing to wages: how employers can reduce health spending and provide greater economic security.
    Robertson CT
    Yale J Health Policy Law Ethics; 2014; 14(2):239-95. PubMed ID: 25486714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prescription drugs: issues of cost, coverage, and quality.
    Copeland C
    EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ACA's Zero Cost-Sharing Mandate and Trends in Out-of-Pocket Expenditures on Well-Child and Screening Mammography Visits.
    Kirby JB; Davidoff AJ; Basu J
    Med Care; 2016 Dec; 54(12):1056-1062. PubMed ID: 27479595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program.
    Anderson GM; Kerluke KJ; Pulcins IR; Hertzman C; Barer ML
    Inquiry; 1993; 30(2):199-207. PubMed ID: 8314608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation.
    Motheral BR; Henderson R
    Am J Manag Care; 1999 Nov; 5(11):1383-94. PubMed ID: 10662412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physicians' opinions about responsibility for patient out-of-pocket costs and formulary prescribing in two Midwestern states.
    Khan S; Sylvester R; Scott D; Pitts B
    J Manag Care Pharm; 2008 Oct; 14(8):780-9. PubMed ID: 18983207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of expanded mental health benefits on treatment costs.
    Sasso AT; Lurie IZ; Lee JU; Lindrooth RC
    J Ment Health Policy Econ; 2006 Mar; 9(1):25-33. PubMed ID: 16733269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
    Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.
    Dusetzina SB; Conti RM; Yu NL; Bach PB
    JAMA Intern Med; 2017 Aug; 177(8):1185-1188. PubMed ID: 28558108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How Pharmacy Benefit Managers Add to Financial Toxicity: The Copay Accumulator Program.
    Nabhan C; Phillips EG; Feinberg BA
    JAMA Oncol; 2018 Dec; 4(12):1665-1666. PubMed ID: 30286215
    [No Abstract]   [Full Text] [Related]  

  • 36. Reference pricing for drugs: is it compatible with U.S. health care?
    Kanavos P; Reinhardt U
    Health Aff (Millwood); 2003; 22(3):16-30. PubMed ID: 12757268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Out-of-pocket costs to users: medicine options for hypertension.
    Arredondo A
    Am J Hypertens; 2008 May; 21(5):492. PubMed ID: 18437138
    [No Abstract]   [Full Text] [Related]  

  • 38. PBMs: Criticized But Still Needed.
    Belazi D
    Manag Care; 2019 May; 28(5):47. PubMed ID: 31188112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reducing Branded Prescription Drug Prices: A Review of Policy Options.
    Alexander GC; Ballreich J; Socal MP; Karmarkar T; Trujillo A; Greene J; Sharfstein J; Anderson G
    Pharmacotherapy; 2017 Nov; 37(11):1469-1478. PubMed ID: 28805961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.